SMARCA2 and cancer: The puzzling finding that chronic BRG1 and/or BRM deficiency in these cancer cell lines does not lead to permanent downregulation of GTF2H1, whereas transient depletion does, indicates that there might be an adaptive, compensatory mechanism in these cells that restores GTF2H1 expression to prevent chronic TFIIH dysfunction.